PEAR earnings

Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter operating expenses and cut expected 2023 operating expenses Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022. "Pear is making strong and steady progress toward our mission of making PDTs mainstream medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "

Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of market on Monday, November 14, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the

20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear's commercial products show cost-savings1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022. "Pear continues to make significant progress in introducing PDTs as an innovative class of medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "We believe our evidence generation strategy is de

Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its second quarter 2022 financial results after the close of market on Thursday, August 11, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the

108% quarter-over-quarter revenue growth to $2.7 million >9,200 total prescriptions in the first quarter for Pear's three FDA-authorized products Expanded patient access with state payors in Michigan and Oklahoma CMS issued new HCPCS code Pear's first 12-month and 24-month real-world health economic data presented at ISPOR Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported financial results for its first quarter ended March 31, 2022. "Our momentum in 2021 continued into 2022 with strong revenue and prescription volume growth in the first quarter," said Corey

Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the company will issue its first quarter 2022 financial results after the close of market on Monday, May 16, 2022. The company will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss its financial and business highlights. To access the live conference call via telephone, please dial (877) 814-6630 (U.S. callers) or (409) 216-0625 (international callers) and provide passcode 6975673. A live webcast will also be available in the Investors section of the company's website at www.

$4.2 million total revenue for the full year 2021 2021 highlights include Current Procedural Terminology (CPT) codes for prescribers, first state Medicaid coverage decision, two major PBM formulary additions, more than 30 organizations providing access, and 9-month HEOR data published Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today reported financial results for its fourth quarter and full year 2021 ended December 31, 2021. Fourth Quarter 2021 Financial Results Pear's total revenue for the fourth quarter of 2021 was $1.3 million, compared with $34 thousand for the fou

Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host a conference call and webcast at 4:30 p.m. ET on Monday, March 28, 2022, to discuss its financial and operating results for the fourth quarter and full year of 2021. To access the live conference call via telephone, please dial (877) 814-6630 (U.S. callers) or (409) 216-0625 (international callers) and provide passcode 8586341. A live webcast will also be available in the Investors section of the company's website at www.peartherapeutics.com. A replay of the webcast will be available in the Investors